ACT-HIB

Brand name authorized in: Austria Cyprus Finland France Hong Kong Netherlands Poland

Active ingredients

The drug ACT-HIB contains one active pharmaceutical ingredient (API):

1 Haemophilus influenzae B
UNII FLV5I5W26R - HAEMOPHILUS INFLUENZAE TYPE B STRAIN 1482 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN

Haemophilus influenza type B (Hib) is a bacteria responsible for severe pneumonia, meningitis and other invasive diseases almost exclusively in young children. Vaccines are the only public health tool capable of preventing the majority of serious Hib disease.

Read about Haemophilus influenzae B

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
Haemophilus influenzae B, purified antigen conjugated
J Antiinfectives for systemic use → J07 Vaccines → J07A Bacterial vaccines → J07AG Haemophilus influenzae B vaccines
Discover more medicines within J07AG01

Unique identifiers

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
FI
Lääkealan turvallisuus- ja kehittämiskeskus
Identifier(s): 198901
FR
Base de données publique des médicaments
Identifier(s): 61104024
HK
Department of Health Drug Office
Identifier(s): 37568
NL
Z-Index G-Standaard
Identifier(s): 13901397
NL
Z-Index G-Standaard, PRK
Identifier(s): 36471
PL
Rejestru Produktów Leczniczych
Identifier(s): 100224400